Core Viewpoint - Enovis Corporation has launched the Manafuse® bone growth stimulator, a portable device utilizing low-intensity pulsed ultrasound (LIPUS) technology for non-invasive treatment of fresh fractures and non-union fractures, aiming to accelerate healing processes [1][3][4]. Product Overview - Manafuse® stimulates the body's natural healing process by emitting LIPUS signals, designed for specific fresh fractures and non-union fractures, excluding cranial and vertebral bones [3][4]. - The device is portable, battery-operated, and requires only 20 minutes of daily use, with a maximum usage period of 343 days, making it suitable for home use [4]. - LIPUS technology has 30 years of clinical evidence supporting its effectiveness in improving fracture healing [4][7]. Clinical Data - A prospective, randomized, double-blind, placebo-controlled study indicated that LIPUS treatment can accelerate healing by 38%, with a difference of over 8 weeks [9]. - Clinical studies report a success rate of up to 86% for Manafuse in treating non-union fractures [9]. Market Overview - The global bone growth stimulator market is projected to grow from $1.4 billion in 2022 to $1.8 billion by 2027, with a compound annual growth rate (CAGR) of 5.9% [13]. - Key growth drivers include an increasing target patient population, rising sports and orthopedic-related injuries, and an aging population [13]. - Major competitors in the market include Orthofix Medical Inc., ZimVie, Bioventus LLC, Medtronic, Stryker, and DePuy Synthes [13]. Financial Performance - Enovis reported a loss of $703.3 million, with a net loss attributed to a non-cash goodwill impairment charge of $645 million related to its Recon and P&R business segments [22]. - Despite a 23.3% increase in sales to approximately $561 million, the company faced significant net losses [22]. - Adjusted earnings per share are expected to be between $3.10 and $3.25 for 2025, with sales projected between $2.19 billion and $2.22 billion [22].

Core Viewpoint - Zimmer Biomet Holdings, Inc. will host its second quarter earnings conference call on August 7, 2025, at 8:30 a.m. ET, with a news release detailing the quarterly results available at 6:30 a.m. ET on the same day [1]. Company Overview - Zimmer Biomet is a global leader in medical technology, offering a comprehensive portfolio aimed at maximizing mobility and improving health [3]. - The company has over 90 years of trusted leadership and expertise, focusing on delivering high-quality solutions to patients and providers [4]. - Zimmer Biomet operates in more than 25 countries and has sales in over 100 countries, emphasizing its extensive global reach [5].

Summary of Conference Call for Zimmer Biomet Industry and Company Overview - The conference call involved Zimmer Biomet, a company in the orthopedic medical device industry, focusing on product launches and financial guidance for 2025 [1][2]. Key Points and Arguments Tariff Impact - Estimated overall tariff impact for 2025 is between $60 million to $80 million, primarily affecting the second half of the year [5][6]. - Key assumptions include a 10% baseline tariff globally, with specific higher tariffs on products from China and the U.S. [5][9]. - The company is taking a conservative approach regarding the Nairobi protocol, not speculating on its applicability [8][12]. - The situation regarding tariffs remains fluid, and updates will be provided in the second quarter call [6][7]. Financial Guidance and Growth Projections - The company is confident in achieving organic, constant currency revenue growth of 3% to 5% for 2025, despite a slower first quarter growth of approximately 2.3% to 2.4% [18][19]. - The second half of 2025 is expected to show stronger growth due to favorable comparisons and new product launches [19][20]. - New product introductions, referred to as the "Magnificent Seven," are anticipated to significantly impact growth in the latter half of the year [19][20]. New Product Launches - Strong momentum is noted in the hip product category, particularly with the triple taper hip stem and AI navigation products [31][32]. - The company expects robust growth in knee products in the second half of the year, particularly with Persona Osteo Tie and robotics [32][33]. - The market for cementless knees is underpenetrated, with expectations for increased adoption due to better fixation rates and surgical efficiency [35][36]. Competitive Landscape - Zimmer Biomet remains the number one company in the knee and hip markets, despite competitive pressures from companies like Smith & Nephew and J&J [42][43]. - The company is focused on maintaining its leadership position through new product innovations and strategic investments [43]. Leadership and Organizational Changes - A new head of U.S. commercial operations has been appointed, emphasizing an evolutionary approach rather than radical changes [44][46]. - The leadership team is confident in executing the 2025 plan and long-range plan (LRP) [47][48]. Acquisition Strategy - The integration of Paragon 28 is progressing well, with no talent loss and positive opportunities in the ASC environment [50][51]. - The company aims for responsible M&A to achieve a 5% WEMGARD growth rate by 2027, with a focus on organic growth as well [54][55]. Financial Performance and Margins - The company has consistently grown earnings at a rate of 5% to 9% over the past four years, with expectations to replicate this growth in 2025 [69][70]. - Gross margins are expected to remain stable despite potential headwinds from tariffs and currency fluctuations [72][73]. Stock Buybacks and Capital Deployment - The company is open to opportunistic stock buybacks, balancing this strategy with M&A opportunities [82][83]. Other Important Content - The company is focused on reallocating resources effectively to enhance growth, with a significant investment in innovation [60][66]. - The management emphasizes the importance of maintaining a strong balance sheet to support ongoing and future growth initiatives [84][85].

Core Viewpoint - Zimmer Biomet's shares have underperformed the S&P 500, losing about 0.5% in the past month, raising questions about its upcoming earnings release and potential for a breakout [1]. Group 1: Earnings Estimates and Trends - Fresh estimates for Zimmer Biomet have trended downward over the past month, indicating a negative outlook [2][4]. - The stock has a Zacks Rank of 4 (Sell), suggesting expectations of below-average returns in the coming months [4]. Group 2: VGM Scores - Zimmer Biomet has an average Growth Score of C, a Momentum Score of F, and a Value Score of B, placing it in the top 40% for value investment strategy [3]. - The aggregate VGM Score for Zimmer is C, which is relevant for investors not focused on a single strategy [3]. Group 3: Industry Performance Comparison - In comparison, Stryker, a competitor in the same medical products industry, has gained 0.9% over the past month and reported revenues of $5.87 billion, reflecting a year-over-year increase of 11.9% [5]. - Stryker's earnings per share (EPS) for the last quarter was $2.84, up from $2.50 a year ago, and it is expected to post an EPS of $3.06 for the current quarter, representing a year-over-year change of 8.9% [5][6].

Core Viewpoint - Zimmer Biomet (ZBH) is focusing on strategic priorities, new product launches, and international expansion, which enhances confidence in the stock despite macroeconomic challenges and foreign exchange issues [1] Group 1: Favorable Factors - The global musculoskeletal market is showing gradual stability with better-than-expected sales growth in certain regions, driven by improved procedural volume and favorable demographics [2] - In Q1 2025, Zimmer Biomet experienced strong growth due to continued procedure growth and solid momentum from new innovations, with large joints business growing 1.9%, 2.4%, and 4.9% for Knees, Hips, and S.E.T. respectively at constant exchange rates [3] Group 2: Expansion Strategy - Zimmer Biomet is implementing a four-pillar expansion strategy aimed at achieving a 5% weighted average market growth rate by 2027, which includes boosting patient awareness, enhancing safety, improving efficiency, and elevating outcomes [4][5] - The company has completed the acquisition of Paragon 28, which is expected to add 270 basis points to sales growth in 2025 [6] Group 3: Stock Performance - Over the past three months, ZBH shares have declined by 6.3%, while the industry has gained 1.5%, but strategic market expansion and new product launches are expected to help regain momentum [7] Group 4: Challenges - Industry-wide staffing shortages and supply chain issues are negatively impacting growth, compounded by geopolitical complications affecting raw material and labor costs [8] - The ongoing tariff issue is projected to impact 2025 operating profit by $60–$80 million, with full-year adjusted operating margins expected to decrease by 100–150 basis points compared to 2024 [9] - A significant portion of Zimmer Biomet's foreign revenues is affected by the strong U.S. dollar, with Q1 2025 net sales impacted by 1.2% due to foreign exchange rate changes [10]

Financial Data and Key Metrics Changes - Product revenue increased by 97% to $4.7 million for the first half of fiscal year 2025 compared to $2.4 million in the same period of fiscal year 2024 [4][13] - Product gross margins improved to 57.9%, more than double the gross margin of 27.9% in the first half of fiscal year 2024 [4][14] - Net loss for the second quarter of fiscal year 2025 improved to $2.3 million or $0.07 per share, compared to a net loss of $2.9 million or $0.11 per share in the same quarter of the prior fiscal year [16] Business Line Data and Key Metrics Changes - The company reported a product revenue of $1.4 million in the second quarter of fiscal year 2025, consistent with the same quarter in fiscal year 2024 [13] - License revenue of $3 million was recognized in the first six months of fiscal year 2025, compared to no license revenue in the same period of fiscal year 2024 [14] Market Data and Key Metrics Changes - The company is focusing on expanding its market presence through strategic partnerships, particularly with Zimmer Biomet, which includes exclusive distribution rights in the U.S. and certain other countries [8][9] - The company is initiating a process to secure ISO 13485 certification to commercialize and obtain regulatory approvals internationally, which could represent significant revenue in the future [9] Company Strategy and Development Direction - The company aims to achieve mass adoption of its technology by fostering relationships with initial targeted sites and expanding to new centers [6] - The company is pursuing additional applications for its technology platform, including spinal cord nerve ablation and spinal cord stimulation for back pain management [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow breakeven if key milestones are met, reiterating fiscal year 2025 guidance of product revenue between $8 million and $10 million [11][10] - The company believes that the FDA clearance of its trigeminal nerve ablation system could generate revenues as soon as late calendar year 2025 [8] Other Important Information - The company has no debt and anticipates being fully funded through at least fiscal year 2026, following a successful capital raise that added $8.2 million in net proceeds [10][17] - The addition of a chief medical advisor is expected to enhance product development and clinical outcomes tracking [24] Q&A Session Summary Question: Clarification on revenue guidance excluding licensing fee - The guidance of $8 million to $10 million excludes the $3 million licensing fee received in the first quarter [20] Question: Revenue sources for the current year - Almost all revenue is expected to come from the Zimmer Biomet agreement, with only about 6% from early centers in the first half of the year [21] Question: Current cash position - As of April, the company had $9.4 million in cash on hand, including recent financing [22] Question: Significance of adding a chief medical advisor - The chief medical advisor's clinical background aligns with the company's current and future clinical areas, aiding in product development and patient outcomes tracking [23][24]

Financial Data and Key Metrics Changes - Product revenue increased 97% to $4,700,000 for the first half of fiscal 2025 compared to $2,400,000 for the same period in fiscal 2024 [5][15] - Product gross margins improved to 57.9%, more than double the gross margin in the first half of fiscal 2024 [5] - Net loss for the second quarter improved to $2,300,000 or $0.07 per share compared to a net loss of $2,900,000 or $0.11 per share in the same quarter of the prior fiscal year [18] - Total operating expenses decreased 4% to $6,700,000 for the first six months of fiscal 2025 compared to $6,900,000 in the same period of fiscal 2024 [17] Business Line Data and Key Metrics Changes - The company recognized $3,000,000 in license revenue in the first six months of fiscal 2025, derived from the expanded exclusive distribution agreement with Zimmer [16] - Product gross profit for the second quarter was $800,000 or 55.6% of revenue, compared to $400,000 or 28.3% of revenue in the second quarter of fiscal 2024 [16] Market Data and Key Metrics Changes - The company is targeting the trigeminal nerve ablation market, with approximately 150,000 people diagnosed with trigeminal neuralgia annually in the U.S. [8] - The company is initiating a process to secure ISO 13485 certification for international commercialization, which could represent significant revenue in the future [11] Company Strategy and Development Direction - The company aims to achieve mass adoption of its technology by fostering relationships with initial targeted sites and expanding to new centers [7] - The strategic partnership with Zimmer includes exclusive distribution rights in the U.S. and certain additional countries for the 1RF ablation system [10] - The company is exploring additional applications leveraging its platform technology, including spinal cord nerve ablation and stimulation [10] Management's Comments on Operating Environment and Future Outlook - Management reiterated fiscal year 2025 guidance, expecting product revenue to be in the range of $8,000,000 to $10,000,000, representing an increase of 132% to 190% over fiscal 2024 [13] - The company believes it is fully funded through at least fiscal 2026 and could reach cash flow breakeven if key milestones are achieved [12] Other Important Information - The company has no debt and has bolstered its balance sheet with $8,200,000 in net proceeds from a successful capital raise [12][19] - The addition of a chief medical advisor is expected to enhance product development and clinical requirements [25][26] Q&A Session Summary Question: Is the guidance excluding the $3 million from the first quarter? - Yes, it is correct that the guidance excludes the licensing fee received in the first quarter [21] Question: Will revenue for the full year come from Zimmer Biomet? - Almost entirely from Zimmer Biomet, with about 6% of revenue from early centers in the first half [23] Question: What is the current cash position? - As of April, the company had $9,400,000 in cash on hand [24] Question: What is the significance of adding a chief medical advisor now? - The chief medical advisor's clinical background fits perfectly with the company's current and future areas, including product development and patient outcome tracking [25][26]

Core Insights - Zimmer Biomet Holdings, Inc. reported better-than-expected earnings for Q1, with adjusted EPS of $1.81, down from $1.94 a year ago, surpassing Street estimates of $1.77 [1] - The company achieved sales of $1.91 billion, reflecting a 1.1% increase on a reported basis and a 2.3% increase on a constant currency basis, nearly aligning with the consensus of $1.9 billion [1] Financial Guidance - For fiscal year 2025, the company expects adjusted EPS in the range of $7.90-$8.10, a decrease from the previous guidance of $8.15-$8.35, compared to consensus expectations of $8.19 [2] - Revenue growth for 2025 is projected at 5.7% – 8.2%, an increase from the earlier expectation of 1% – 3.5%, with a foreign currency exchange impact anticipated between 0.0% and 0.5% [3] Stock Performance and Analyst Ratings - Following the earnings announcement, Zimmer Biomet shares increased by 0.7%, trading at $91.08 [3] - Analysts have adjusted their price targets for Zimmer Biomet, with Baird lowering it from $130 to $115, Wells Fargo from $113 to $98, JP Morgan from $128 to $105, and others making similar reductions [8]

Group 1 - Zimmer Biomet's stock fell nearly 10% following the release of weak first quarter results and a significant reduction in full year earnings guidance [1] - The company is currently facing a range of factors impacting its business, leading to the reported weakness [1] - Narweena, an asset manager, focuses on identifying market dislocations due to poor understanding of long-term business prospects, aiming for excess risk-adjusted returns through secular growth opportunities [1] Group 2 - Narweena's research emphasizes company and industry fundamentals to uncover unique insights, with a high risk appetite and long-term investment horizon [1] - The aging population, low population growth, and stagnating productivity growth are expected to create new investment opportunities, differing from past trends [1] - Many industries may experience stagnation or secular decline, which could paradoxically enhance business performance due to reduced competition [1] Group 3 - The economic landscape is increasingly characterized by asset-light businesses, leading to a declining need for infrastructure investments over time [1] - A large pool of capital is pursuing a limited set of investment opportunities, resulting in rising asset prices and compressed risk premia [1] - Richard Durant, the leader of Narweena, holds degrees in engineering and finance, along with an MBA, and has passed the CFA exams [1]

Financial Performance - Net sales for the three-month period ended March 31, 2025, increased by 1.1% year-over-year, totaling $1,909.1 million, driven by market growth and new product introductions [109][114]. - Net earnings rose to $182.0 million in the same period, up from $172.4 million, primarily due to lower restructuring charges and increased net sales [110]. - The company expects revenue growth of 5.7% to 8.2% in 2025, influenced by the Paragon 28 acquisition and new product launches [111]. - Changes in volume and mix of product sales positively affected year-over-year sales by 2.2% during the three-month period ended March 31, 2025 [116]. - International net sales increased by 0.7% year-over-year, totaling $795.5 million, despite a negative impact of 3.0% from foreign currency exchange rates [119][114]. Costs and Expenses - Anticipated additional expenses related to tariffs in 2025 are estimated between $60 million to $80 million, impacting costs significantly in the second half of the year [112]. - The cost of products sold as a percentage of net sales increased to 28.8% from 27.1% due to higher manufacturing costs driven by inflation [121]. - Research and development expenses increased to 5.8% of net sales, reflecting higher spending on technology-based projects [122]. - Operating profit as a percentage of net sales decreased in the Americas to 51.8% from 53.9% due to higher manufacturing costs and bad debt charges [130][131]. - Operating profit in EMEA decreased due to higher manufacturing costs, partially offset by restructuring savings [132]. - Operating profit in Asia Pacific also decreased, attributed to higher manufacturing costs and increased bad debt-related charges [133]. Cash Flow and Financing - Cash flows from operations were $382.8 million for the three-month period ended March 31, 2025, up from $228.0 million in the prior year [136]. - Cash flows used in investing activities decreased to $106.0 million from $195.0 million year-over-year, reflecting lower investments in property and equipment [137]. - Cash flows provided by financing activities were $575.4 million, with senior notes issued for proceeds of $1,748.1 million [138]. - As of March 31, 2025, the company had $1,384.5 million in cash and cash equivalents, with $1.0 billion available to borrow under a credit agreement [134]. - Outstanding debt as of March 31, 2025, was $7,176.3 million, with $600.0 million classified as current debt maturing on January 15, 2026 [142]. Strategic Initiatives - The company completed the acquisition of Paragon 28 for approximately $1.4 billion, utilizing cash and borrowing [143]. - The 2025 Restructuring Plan is expected to incur pre-tax charges of approximately $85 million, aiming to reduce annual operating expenses by $95 million by the end of 2027 [146]. - The company declared a quarterly cash dividend of $0.24 per share and has $1,020.2 million remaining under a $2.0 billion share repurchase program [145]. Taxation - The effective tax rate for the three-month period ended March 31, 2025, was 20.3%, up from 19.7% in the prior year, influenced by the mix of earnings between U.S. and foreign locations [129].